Malignant melanoma is a highly aggressive and drugresistant cancer. Virotherapy is a novel therapeutic strategy based on cancer cell lysis through selective virus replication. However, its clinical efficacy is modest, apparently related to poor virus replication within the tumors. We report that the growth compromised herpes simplex virus type 2 (HSV-2) mutant, DPK, has strong oncolytic activity for melanoma largely caused by a mechanism other than replication-induced cell lysis. The ratio of dead cells (determined by trypan blue or ethidium homodimer staining) to cells that stain with antibody to the major capsid protein VP5 (indicative of productive infection) was 1.8-4.1 for different melanoma cultures at 24-72 h post-infection. Cell death was due to activation of calpain as well as caspases-7 and -3 and it was abolished by the combination of calpain (PD150606) and pancaspase (benzyloxycarbonyl-Val-AlaAsp-fluormethyl ketone, z-VAD-fmk) inhibitors. Upregulation of the autopahgy protein Beclin-1 and the pro-apoptotic protein H11/HspB8 accompanied DPK-induced melanoma oncolysis. Intratumoral DPK injection (10 6 -10 7 plaque-forming unit (pfu)) significantly reduced melanoma tumor burden associated with calpain and caspases-7 and -3 activation, Beclin-1 and H11/HspB8 upregulation and activation of caspase-1-related inflammation. Complete remission was seen for 87.5% of the LM melanoma xenografts at 5 months after treatment termination. The data indicate that DPK is a promising virotherapy for melanoma that functions through virus-induced programmed cell death pathways.
Introduction
Malignant melanoma is a commonly diagnosed highly aggressive and drug-resistant cancer that accounts for B75% of cancer skin deaths. 1 Poor prognosis is likely related to the failure of conventional therapies to eradicate cancer stem cells that are responsible for resistance, invasiveness and neoplastic progression. 2 Oncolytic viruses are recognized as a promising novel therapy designed to reduce tumor burden by direct cell lysis resulting from virus replication and the generation of infectious progeny that spreads throughout the tumor. 3, 4 Virotherapy may also disrupt the tumor vasculature and induce antitumor immunity, 3, 4 and it carries the promise of targeting cancer stem cells. 5 Originally developed to target neuronal cancers, the herpes simplex virus (HSV) oncolytic constructs were generated from HSV-1 through deletion/modification of the neurovirulence protein, ICP34.5, and/or the large subunit of ribonucleotide reductase (R1). Early clinical trials have shown that oncolytic viral therapies are tolerated well, but their efficacy is modest, apparently related to poor virus replication within the tumors. 6 Accordingly, ongoing efforts have focused on improving virus replication through: (i) fusogenic alterations that increase virus uptake/spread, 7 (ii) modulation of the tumor milieu, 8 (iii) suppression of innate immunity or interference with virus-mediated immune evasion, 9 (iv) expression of immunostimulatory cytokines, 10 and (v) use of cytotoxic drugs in combinatorial therapy. 9, 11 However, it is becoming increasingly evident that the development of oncolytic viruses with distinct molecular death functions is highly desirable. Our studies were designed to address this need. They are based on the hypothesis that virotherapy strategies that function through the induction of multiple nonredundant programmed cell death (PCD) pathways provide cancer cell killing selectivity and increase virus spread through the tumor mass 12 while avoiding the replication-related limitations of conventional oncolytic viruses. Development of a PCD-based virotherapy is particularly desirable for melanoma, which is resistant to a wide spectrum of therapeutic modalities, 13 including canonical oncolytic viruses that function through replication-dependent cell lysis 14 and evades immune recognition through its suppressive milieu/potential. 15 Apoptosis is the best-studied PCD pathway. It is generally mediated by caspases, which are cysteine proteases that are activated by cleavage of precursors or by autocatalysis. 16 Caspase-independent PCD mediated by another protease family known as calpains was also reported. 17 Other PCD pathways include autophagy, which has a major role in cell homeostasis and can cross talk with apoptosis 18 and pyroptosis, a caspase-1-dependent inflammatory process that can activate apoptosis through the pro-inflammatory cytokine tumor-necrosis factor alpha (TNF-a). 19 Beclin-1, which is required for autophagy induction, acts as a haploinsufficient tumor suppressor protein, the expression of which is inhibited in some human tumors. 20, 21 The HSV type 2 (HSV-2) protein, ICP10 (encoded by the UL39 gene), has a protein kinase (PK) function that overrides multiple nonredundant PCD pathways in cultured cells and animal models, suggesting that these pathways are likely to be activated by its deletion. [22] [23] [24] [25] [26] [27] We focused on the ICP10PK-deleted virus DPK, because it is known to trigger cell-specific apoptosis 22 and it has strong immunotherapeutic activity mediated by the induction of CD4+ T-helper type 1 (Th1) cells 28 that override the Th2 type response characteristic of melanoma. 29 DPK also has the distinct advantage that it is tolerated well in human patients. 30 , 31 Here, we report that DPK has robust melanoma oncolytic activity in culture and in animal models (xenografts) through the simultaneous activation of multiple nonredundant PCD pathways. These pathways include the activation of distinct proteases and are associated with upregulation of the autophagy protein Beclin-1 and the proapoptotic protein H11/HspB8 previously shown to cause melanoma cell apoptosis 32 and activation of caspase-1-related pyropotosis. To the extent of our knowledge, this is the first report that an HSV oncolytic virus causes tumor cell death by these mechanisms, notably in melanoma.
Results

DPK has tumor-selective growth
DPK is growth restricted in Vero (African green monkey kidney) cells cultured in low serum, a property associated with its failure to activate Ras signaling pathways. 33, 34 As the Ras and B-Raf pathways are activated in most melanoma cultures, 35 we wanted to know whether they compensate for virus growth, providing conditions that enable the tumor selectivity characteristic of oncolytic viruses. We studied a panel of nine human melanoma cultures that includes established (A2058, A375, SKMEL-2, MeWo) and freshly prepared lines (LM, SM, LN, OV, BUL) with different patterns of activated ERK and/or Akt (Supplementary data, Figure S1 ). Controls were Vero cells, which grow in agarose and cause tumors in animals, at least at a relatively high passage 36 and normal human lung fibroblasts (WI-38) and melanocytes, both of which are primary growthlimited cultures. The cells were infected with DPK (multiplicity of infection (moi) ¼ 0.5) and assayed for virus growth by plaque assay, as described in Materials and methods. Consistent with previous findings, 33 ,34 the growth of HSV-2 and the revertant virus HSV-2(R) began at 4 h post-infection (p.i.) and reached a maximal burst size (976 ± 12 plaque-forming unit (pfu) per cell) at 24 h p.i. By contrast, the growth of DPK began at 12 h p.i. and reached maximal, albeit low levels (1.1 ± 0.1 pfu per cell) at 36 h p.i. (Figure 1a ). This temporal restriction was released in melanoma cultures, as shown for A2058, MeWo, SM and A375 cells, with growth beginning at 4 h p.i. as determined both by the burst size (pfu per cell) ( Figure 1b ) and staining with antibody to the major capsid protein VP5 (Figure 1c) . However, the maximal yields of infectious virus (1.1 ± 0.2 pfu per cell) seen at 18-24 h p.i. were similar to those seen in Vero cells (Figure 1b) . The number of VP5+ cells was also relatively low (16±1% at 48 h p.i.) and similar results were obtained for melanoma cultures LM, SKMEL-2, LN, OV and BUL. This was unrelated to the ability of DPK to infect the cells, because the percentage of cells staining with ICP10 antibody (recognizes the PK deleted ICP10 protein, also known as p95), which is regulated with immediate early (IE) kinetics and is expressed in the absence of VP5, 37, 38 was consistent with the rate of infection for the studied moi (25±5% as early as 4 h p.i.) (Figure 1c) . DPK did not grow in WI-38 cells (Figure 1b) but there was a similar percentage of cells staining with ICP10 antibody (27 ± 3%, Figure 1c) , indicative of infection. Normal melanocytes behaved like WI-38 cells (data not shown). These findings are in contrast to those obtained for HSV-2 and HSV-2(R), the growth of which was similar to that seen in Vero cells for all the studied cultures (921±54 and 737±28 pfu per cell, respectively, at 24 h). Collectively, the data indicate that DPK has selective, albeit relatively low growth potential for transformed/tumor cells.
DPK-induced melanoma oncolysis includes a robust component other than virus replication
The DPK-infected melanoma cultures were examined for cell death by morphology (cytopathogenic effect (CPE)), trypan blue exclusion and ethidium homodimer-1 (EtHD-1) staining at 0-72 h p.i. Cultures mock-infected with phosphate-buffered saline (PBS) and DPK-infected freshly isolated normal melanocytes and WI-38 cells were studied in parallel and served as controls. DPK caused a time-dependent increase in CPE in all the melanoma cultures, with virtually all cells becoming rounded, refractile and detached by 72 h p.i. This was accompanied by increased staining with trypan blue (85-95% positive cells at 72 h p.i.) or EtHD-1 (63-85% positive cells at 72 h p.i.) and similar results were obtained for cultures grown in serum-free medium or in medium supplemented with 10% fetal bovine serum (FBS) (Figures 2a and b) . Duplicate cultures obtained at the same times were stained with antibody to VP5 (Figure 1c ) and the percentage of dead cells (trypan blue and/or EtHD-1+) was evaluated relative to the percentage of VP5 staining cells. The ratio of trypan blue+ or EtHD-1+/VP5+ cells (Figures 1c and 2 ) ranged between 1.8 and 4.1 for the different cultures at 24-72 h p.i., with an average of 2.8, suggesting that a major component of cell death is through a program other than lysis caused by productive virus replication (replication bystander effect). In this context, it is important to point out that VP5 also did not colocalize with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), a marker of canonical apoptosis, which was a relatively minor component (12.4 ± 1.1% cells at 48 h p.i.) of the DPK bystander effect (Supplementary data, Figure S2 ). DPK-infected primary melanocytes and WI-38 cells did not stain with trypan blue or EtHD-1 (3.4-5.7% positive cells throughout the study interval) (Figure 2b ), supporting the conclusion that DPK-induced cell death is selective for cancer/transformed cells. Similar results were obtained with virus purified as previously described. 39 Calpain and caspases-7 and -3 are activated in DPK-infected melanoma cultures
Having seen that DPK-mediated melanoma cell death includes a component other than virus replication, we considered the possibility that this component involves PCD. We considered caspases-3 and -7, which occupy nonredundant roles within the cell death machinery 40 and calpains, which act through different PCD pathways independently or in cooperation with the caspases. 17, 27 Extracts of melanoma cells infected with DPK for 0-24 h were immunoblotted with antibodies to calpain and caspases-7 and -3, and the results were quantitated by densitometric scanning, as described in Materials and DPK oncolysis in melanoma AG Colunga et al methods. As shown for A2058 cells, DPK caused sequential and apparently independent activation of these three proteases. Calpain activation, expressed as an increased ratio of the active (p76) to inactive (p80) forms of the catalytic subunit, was first seen at 1 h p.i. and it was followed at 24 h p.i. by the loss of the p28 regulatory subunit, which is another marker of enzyme activation 41 ( Figure 3a) . Activation of caspase-7 was first seen at 4 h p.i., as evidenced by the appearance of the caspase-7p20 cleavage product, and it continued with time p.i., with the smaller p17 and p11 breakdown products seen at 24 h p.i. Activation of caspase-3 was first seen at 24 h p.i., and it appeared to be less robust than that seen for caspase-7, as determined by the levels of the respective cleavage products ( Figure 3b ).
As calpain can attenuate or facilitate the activity of the caspases 42, 43 and it is activated before them, we wanted to know whether calpain activation contributes to the ability of DPK to activate the caspases. Extracts from duplicate cultures infected with DPK in the absence or presence of the calpain inhibitor, PD150606 (100 mM), were immunoblotted with antibodies to calpain followed by caspases-7 and -3. Calpain activation was inhibited by PD150606, as evidenced by reduced p76/p80 ratios and retention of p28 (Figure 3a) . By contrast, the levels of the caspase cleavage products (caspase-7p17 and p11 and caspase-3p17) were increased, at least at 24 h p.i. (Figure 3b ). This is not a technical artifact, because caspase activation was inhibited by the pancaspase inhibitor, benzyloxycarbonyl-Val-Ala-Asp-fluormethyl ketone (z-VAD-fmk) (100 mM, Sigma-Aldrich (St Louis, MO, USA); 20 mM Promega (Madison, WI, USA)), as shown for caspase-7 in Figure 3c . z-VAD-fmk did not affect calpain activation, and neither PD150606 nor z-VAD-fmk had any effect on virus growth (data not shown). Similar results were obtained for all the studied melanoma cultures, both in terms of protease activation and its inhibition. Collectively, the data indicate that calpain reduces, but does not abrogate the ability of DPK to cause caspase activation, supporting the interpretation that these are independent events.
DPK-induced oncolysis is calpain and caspase dependent
To examine the role of the activated proteases in DPK-induced melanoma cell death, the cultures were mock-infected with PBS or infected with DPK in the absence or presence of PD150606 or/and z-VAD-fmk and cell death was determined at 0-72 h p.i. by EtHD-1 staining. As shown in Figure 4 for A2058 and A375 cells, DPK caused a time-dependent increase in the percentage of EtHD-1+ cells that reached maximal levels at 72 h p.i. (70.1 ± 5.4 and 78.4 ± 6.8%, respectively). This percentage was significantly decreased by PD150606 (30.7 ± 2.8 and 49.1 ± 2.5% for A2058 and A375 cells, respectively) or z-VAD-fmk (35.8 ± 2.5 and 49.6 ± 3.7% for A2058 and A375 cells, respectively), but cell death was abrogated in cells treated with the combination of both inhibitors. The data indicate that calpain and caspase activation contribute to DPK-induced melanoma oncolysis in an additive manner, supporting the conclusion that the two death pathways function independently.
DPK inhibits the growth of melanoma xenografts
To examine whether DPK has oncolytic activity in melanoma xenografts, A2058, A375 and LM cells were implanted into Balb/c nude mice by subcutaneous injection into both flanks. The animals were given intratumoral injections (100 ml) of partially purified DPK (10 6 and 10 7 per injection) or culture medium control. A total of four injections were given at weekly intervals beginning when the tumors were palpable (B200 mm 3 , day 14 for A2058 and day 7 for A375 and LM xenografts). The virus dose is unrelated to the specific cell line in which it was used and was chosen in order to determine an efficacy range. Tumor volume was calculated as described in Materials and methods. All the mock-treated xenografts evidenced time-dependent growth, with A2058 reaching maximal volume at 42 days (Figure 5a ), A375 at 35 days (Figure 5b ) and LM at 28 days (Figure 5c ), when the mice were killed. DPK caused a significant (Po0.001) decrease in the growth of all the tumors. In the case of the LM xenografts, complete remission was seen for seven of eight tumors (87.5%) followed for 5 months after the last DPK injection (Figure 5c ). The lone recurrent tumor (seen in one animal) did not reach end-point criteria (1.5 cm in diameter) by this time. Compared with the mock-treated animals, survival was significant (Po0.001), ranging between 80% for A2058 and 100% for LM xenografts, as shown for the latter in Figure 5d .
Inhibition of tumor growth is associated with low levels of sustained virus replication and calpain/caspase activation
Mock-and DPK-treated xenograft tissues were collected at 7 days after the last DPK injection and tissue homogenates were examined for virus replication (infectious virus titers) and activation of calpain and caspases-7 and -3, as described in Materials and methods. Virus titers in the DPK-treated tissues ranged between 2 Â 10 2 and 1.5 Â 10 5 pfu ml À1 . In addition, serial sections encompassing the entire tumor mass stained with VP5 antibody with B18-25% VP5+ cells per section, indicative of relatively good virus penetration. Virus was not isolated from the mock-treated tissues and they did not stain with VP5 antibody (Supplementary data, Figure S3 ). Calpain and caspases-7 and -3 were activated in DPK-but not mock-treated tissues, as evidenced by: (i) increased ratios of the calpain p76/p80 isoforms, (ii) loss of the p28 regulatory subunit, (iii) presence of the caspase-7p20 and p17 cleavage fragments, and (iv) loss of pro-caspase-3p30 ( Figure 6 ). Protease activation is due to DPK and is not an artifact caused by differences in the tumor microenvironment, because activation was not observed in mock-treated tumors and the proteases were also activated by DPK in cultured melanoma cells. Collectively, the data indicate that DPK replicates at relatively low but sustained levels (still seen at 7 days p.i.) in the melanoma xenografts, in which it triggers activation of calpain, as well as caspases-7 and -3.
DPK upregulates Beclin-1 and H11/HspB8 in melanoma cultures and xenografts Two series of experiments were carried out in order to examine whether DPK-induced cell death is also associated with the activation of other death pathways. In the first series, extracts of A2058 cell cultures mockinfected or infected with DPK were immunoblotted with antibodies to the autophagy protein Beclin-1 and the heat shock protein H11/HspB8. Beclin-1 is a critical autophagy protein that is emerging as a potent tumor suppressor and is downregulated in some human tumors. 20, 21 Its expression in melanoma is unknown. H11/HspB8 is a small heat shock protein that is silenced in 50-60% of melanomas and triggers apoptosis on forced expression. 32 The data summarized in Figures 7a and b indicate that Beclin-1 was minimally expressed in mock-infected cultures and there was no expression of H11/HspB8. DPK upregulated both Beclin-1 and H11/HspB8, with the expression first seen at 1 and 4 h p.i., respectively. The second series of experiments examined Beclin-1 and H11/HspB8 expression in melanoma xenografts. Beclin-1 expression was inhibited in four of six mock-treated tumors and DPK caused its upregulation in all the studied xenografts (Figure 7c ). H11/HspB8 expression was also inhibited in the mocktreated xenografts and upregulated in three of five of those treated with DPK (Figure 7d ). Beclin-1 and H11/ HspB8 upregulation is not an artifact caused by the tumor microenvironment, because it was also seen in cultured melanoma cells and it was not seen in the mockinfected tumors.
Caspase-1-related inflammation is associated with DPK oncolysis
Pyroptosis is a caspase-1-dependent inflammatory form of cell death that involves formation of the inflammasome complex and was originally observed in macrophages. 44, 45 As DPK induces production of the proinflammatory cytokine TNF-a in the macrophage-related microglial cells, 46 we wanted to know whether DPKinduced oncolysis is also associated with inflammatory processes, which are a known component of apoptosis. Duplicates of the mock-and DPK-treated xenografts were stained with antibodies to activated caspase-1, CD11b (macrophage marker) and TNF-a, which is known to activate caspase-1, 19 trigger apoptosis and slow the growth of some tumors. 47 Staining with all three antibodies was seen in the DPK, but not mock-treated tissues (Figure 8 ), indicating that caspase-1 activation and inflammation, both of which are considered markers of pyroptosis, 44, 46 are also associated with DPK-induced melanoma oncolysis in vivo.
Discussion
The salient feature of the data presented in this report is the finding that the ICP10PK-deleted virus DPK kills melanoma cells in culture and in animal models through (10 7 ) were implanted subcutaneously into both flanks of Balb/c nude mice and given intratumoral (i.t.) injections (100 ml) of DPK (n ¼ 12; 10 7 plaque-forming unit (pfu)) or growth medium (n ¼ 6; mock) beginning on day 14, when the tumors were palpable (B200 mm 2 ). A total of four injections were given once weekly and tumor volume was calculated as described in Materials and methods. The difference between mock-and DPK-treated animals became statistically significant on day 32 (Po0.001 by two-way analysis of variance (ANOVA)) and remained significant to the end of the study. Representative animals and tumor tissues were photographed at day 42. (b) A375 xenografts were established as in panel a and were given four i.t. injections of DPK (n ¼ 6; 10 6 pfu) or growth medium (n ¼ 6) at weekly intervals beginning on day 7, when the tumors were palpable. The difference between mock and DPK treatment became statistically significant at day 23 and remained significant by the end of the study (Po0.001 by two-way ANOVA). (c) LM melanoma cells (10 7 ) were implanted subcutaneously into both flanks of Balb/c nude mice and were given four i.t. injections of DPK (n ¼ 6; 10 6 pfu) or growth medium (n ¼ 6; mock) at weekly intervals beginning on day 7, when the tumors were palpable. Tumor volume in four animals was monitored for 5 months after the last DPK injection. The difference between mock and DPK treatment became statistically significant on day 14 (Po0.001 by two-way ANOVA) and remained significant to the end of the study. Three DPK-treated mice showing complete tumor eradication were photographed at day 35. (d) Kaplan-Meier survival analysis in animals given LM xenografts with the terminal event set at 1.5 cm diameter of growth in any one direction. DPK is significantly different from mock (Po0.001) by LogRank (Mantel-Cox) analysis.
DPK oncolysis in melanoma AG Colunga et al activation of functionally distinct proteases (nonredundant PCD pathways) and in association with upregulation of Beclin-1, H11/HspB8 and caspase-1-related inflammation. The following comments seem pertinent with respect to these findings. Oncolytic viruses are engineered and selected to exploit genetic defects in tumor cells that enable selective virus replication. They are designed to reduce the tumor burden by cell lysis resulting from virus replication and the generation of infectious virus progeny that spreads throughout the tumor mass. 3, 4 Their therapeutic promise includes the ability to lyse cancer stem cells 2, 5 and stimulate antitumor immunity. 3, 4 HSV is a particularly promising oncolytic virus because it has a broad host spectrum, is cytolytic, its genome does not integrate into the cellular genome precluding insertion mutagenesis and antiviral drugs are available to safeguard against unfavorable virus replication. However, cumulative data, including early clinical trials, indicate that the therapeutic benefits of virotherapy are modest. 6 As oncolytic viruses are expected to spread through the tumor mass lysing the cells through productive replication, their limited efficacy was attributed to inhibition of replication by antiviral immunity, incomplete dissemination in the tumor mass, and the failure to replicate in quiescent cells, which are the majority of cells in the tumor at any one time. 48, 49 Although ongoing efforts are focused on improving virus replication, it is becoming increasingly evident that the development of oncolytic viruses with distinct molecular death functions is highly desirable.
Our studies follow on recent findings that cancer cell death enhances the penetration and efficacy of oncolytic viruses. 12 They are based on the proposition that oncolytic viruses that induce multiple PCD pathways, which are not the direct outcome of productive virus replication, have increased therapeutic efficacy and are not subject to the limitations currently ascribed to canonical virotherapy. We focused on melanoma, a highly aggressive and drug-resistant cancer of neural crest origin that does not respond to replication-based conventional virotherapy, 14, 50 and on DPK, an HSV-2 mutant that triggers apoptosis in neurons. 22 DPK differs from the recently described HSV-2 oncolytic construct FusOn-H2, both in its construction and properties. DPK is deleted in the ICP10 kinase catalytic domain but it retains its transmembrane domain, which is required for membrane localization, protein function and virion stability. 33, [51] [52] [53] The kinase-deleted ICP10 protein (also known as p95) is present in the virion tegument preserving the structural integrity required for optimal virus uptake and thereby, tumor penetration. 51 p95 expression is directed by the authentic ICP10 promoter Figure 6 Calpain and caspases-7 and-3 are activated in DPK-treated xenografts. A2058 xenograft tissues mock-treated or treated with DPK as in Figure 5a were collected 7 days after the last DPK injection and extracts were immunoblotted with antibodies to calpain (a) stripped and sequentially re-blotted with antibodies to activated caspase-7 (b), pro-caspase-3 (c) and actin. Each lane represents a different tumor. Representatives of three replicate experiments are shown for each antibody. Data were quantified by densitometric scanning as described in Materials and methods, and results are expressed as densitometric units (***Po0.001 vs mock).
DPK oncolysis in melanoma AG Colunga et al that has IE kinetics and responds to AP-1 transcription factors, 54 which regulate genes involved in tumor cell apoptosis. 55 DPK does not have any genetic defect other than this deletion, 33, 34 and it has the distinct advantages of: (i) inducing a Th1 response 28 that can override the melanoma Th2-based immunosuppressive milieu, 15, 29 and (ii) being tolerated well in humans. 30, 31 FusOn-H2 differs from DPK in that both the ICP10PK catalytic and transmembrane domains were replaced with EGFP and the resulting protein was placed under the direction of the promiscuous CMV promoter. Most importantly, the virus was selected for fusogenic activity imparted by an unrelated and uncharacterized genetic alteration that is credited with improved virus replication within tumor cells and oncolytic activity. 7, 56 Although DNA fragmentation with 3 0 -OH ends (TUNEL) was reported in one FusOn-H2-treated tumor, 57 fusogenic activity is considered to be a critical mechanism of oncolysis, as reflected by the virus name. 7, 56 Unlike HSV-2 and HSV-2(R) that replicated equally well in all the examined cell types, DPK had selective growth potential in cancer/transformed cells. It replicated in melanoma and Vero cells, but not in normal fibroblasts (WI-38) and melanocytes, at least under the conditions used in these studies. This was not due to the absence of infection, because the percentage of cells staining with antibody to ICP10, which is an IE protein that is expressed in the absence of other viral proteins, 37, 38 was similar to that seen in the melanoma and Vero cultures and consistent with that expected for the used moi. The maximal levels of virus growth in the melanoma cultures was significantly lower than that of DPK-induced cell death, with a trypan blue+ or EtHD+/ VP5+ ratio of 1.8-4.1 for the different cultures at 24-72 h p.i., and similar results were obtained for melanoma cultures with distinct patterns of activated survival/ proliferation pathways. As VP5 staining is a marker of infectious progeny production, the data suggest that cell death was primarily due to a program other than lysis caused by productive virus growth (replication bystander effect). We conclude that the bystander effect was due to activation of nonredundant death programs because: (i) calpain and caspases-7 and -3 were activated in DPKÀ, but not mock-infected cultures, and (ii) cell death was reduced by the calpain inhibitor PD150606 or the pancaspase inhibitor z-VAD-fmk (used at previously established effective doses), but it was only abrogated by the combination of both inhibitors. Calpain activation was first seen at 1 h p.i., when it presented as an increased p76/p80 ratio. It increased with time and, by 24 h p.i., was accompanied by the loss of the regulatory p28 subunit. Interestingly, although caspases-7 and -3 generally compensate for each other and are not simultaneously activated, our data indicate that both were activated by DPK. Activation of caspase-7, was first seen at 4 h p.i. and it increased with time, such that by 24 h p.i., the p20 cleavage fragment was replaced by the lower fragments p17 and p11. Caspase-3 activation was not seen before 24 h p.i. This is consistent with recent reports that these two caspases are differentially activated 58 and they have distinct functions/targets, 40 such that maximal cell death is only seen when both are simultaneously activated. 59 Apoptosis is the best studied PCD and it involves both caspase-dependent extrinsic and intrinsic pathways. 16 However, canonical apoptosis (measured by TUNEL+ cells) was a relatively small component of the DPKinduced cell death. Caspase-independent death pathways were also reported, for example, through AIF release from the mitochondria and its translocation to the nucleus, 17, 27 as was death caused by both caspasedependent and -independent pathways 60, 61 or by distinct PCD pathways, such as autophagy. 62 Calpains are Ca 2+ -dependent neutral cysteine proteases, the relationship of which to the caspases is still poorly understood. Some reports suggest that calpains act independently of the caspases in different PCD pathways, whereas others conclude that they cooperate. In the latter case, calpain activation was found to follow or initiate the activation of the caspases. 27, 63 Calpain cleavage of caspases-9 and -3 was reported to attenuate or facilitate their activity during apoptosis, 42, 43 but more recent data suggest that calpains function in caspase-independent PCD. 60, 64, 65 As activation of calpain and caspase-7 preceded the onset of DPK replication, although activation of caspase-3 was a relatively late event, we assume that distinct virus functions are involved in the activation of the three proteases, at least some of which are independent of a fully productive replicative cycle. In this context, it is important to point out that expression of the IE protein ICP0 was shown to act as an initial inducer of apoptosis, 66 but the contribution of cellular genes 67 that are likely upregulated by distinct virus functions cannot be excluded. Ongoing studies are designed to examine additional melanoma cultures, determine the relative contribution of caspase-7 vs caspase-3 towards melanoma cell death and identify the virus genes/functions that differentially activate the distinct proteases in DPKinfected melanoma cultures.
Significantly, DPK had robust oncolytic activity in melanoma xenografts. The virus was given at a relatively low dose (10 6 -10 7 pfu) but in repeated weekly intratumoral injections, a protocol selected to: (i) favor safety while improving tumor penetration through repeated exposure 68 and (ii) reduce the risk of developing virusresistant melanoma cells resulting from poor killing, as previously described.
14 Although these studies were limited to three melanoma cultures (A2058, A375 and LM), tumor growth was inhibited in all cases with virtually absolute survival (80-100%). In the case of the LM xenografts, complete remission was seen for seven of eight tumors (87.5%) followed for 5 months after the last DPK injection and the lone recurrent tumor did not reach end-point criteria (1.5 cm in diameter) by this time.
Analysis of the DPK-treated xenografts at 7 days after the last injection indicated that a small number of well distributed cells stained with VP5 antibody and the tissues were positive for low titers of infectious virus, indicative of sustained virus replication and relatively good levels of tumor penetration. As was the case for the melanoma cultures, the DPK-treated xenografts were positive for activated calpain and caspases-7 and -3. Interestingly, they also evidenced upregulation of Beclin-1 and H11/HspB8. We conclude that this is not an artifact of the tumor microenvironment, because both proteins were also upregulated in DPK-infected melanoma cultures. In addition, the DPK-treated xenografts were also positive for activated caspase-1 and evidenced increased levels of the pro-inflammatory cytokine TNF-a and infiltrating CD11b+ cells (macrophages). In this context, it is important to point out that the caspase-1 antibody used in these studies is specific for the human protein, suggesting that the activated caspase-1 detected in the DPK-treated xenografts is of melanoma, rather than macrophage origin. The exact contribution of these death-related proteins to melanoma oncolysis is still unclear, but presently available data underscore their potential cross talk with caspase and/or calpain-induced PCD. Autophagy is a process of self-digestion that was reported to cause or protect against cell death 69, 70 and calpain can cleave autophagy proteins, thereby providing a switch between autophagy and apoptosis. 18 The critical autophagy protein Beclin-1 was associated with cell death involving cross talk with Bcl-2 family members 70 and it acts as a haploinsufficient tumor suppressor protein that is downregulated in human tumors. 20, 21 Pyroptosis is a caspase-1-dependent inflammatory form of cell death that involves formation of the inflammasome complex and was originally observed in macrophages. 44, 45 TNF-a, a pro-apoptotic inflammatory cytokine is a death signal and it slows the growth of some tumors. 47 TNF-a can also activate caspase-1 19 and caspase-7 is a caspase-1 substrate. 58 The finding that these death-associated factors coexist with protease activation suggests that they are likely to be independently upregulated/activated by DPK and contribute to oncolysis in vivo, possibly through a positive feedback amplification loop. However, because in cultured cells, oncolysis is abolished through caspase and calpain inhibition, we cannot exclude the possibility that Beclin-1, H11/HspB8 and the inflammatory processes function downstream of calpain and/or caspase. Infectious virus and VP5 staining were not seen in the liver tissues collected at the end of the experimental procedure (data not shown), indicating that there was no systemic toxicity. In fact, DPK was also well tolerated in early clinical trials. 30, 31 Collectively, the data indicate that DPK is a promising melanoma virotherapy strategy in which the relatively limited virus replication is associated with a robust tumor cell killing bystander effect apparently mediated by alternative PCD programs. Ongoing studies are designed to elucidate the role of the various death programs in melanoma cell death in culture and in vivo, to verify whether they differ for distinct melanoma cultures, to examine whether virus-resistant cells, including nestin-1+ cancer stem cells emerge during the course of virotherapy and to determine the role of tumor associated antigens (TAA) load and tumor immunity in the oncolytic activity of DPK.
Materials and methods
Cells and viruses
Melanoma cell lines A2058, A375, MeWo and SKMEL-2 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in Dulbeco's modified Eagle's medium with 10% FBS (Gemini Bioproducts, Calabasos, CA, USA). For A375, A2058 and MeWo, the medium was supplemented with 4.5 g l À1 glucose, 1500 mg ml À1 sodium bicarbonate and 4 mM glutamine. Melanoma cultures LM, SM, LN, OV and BUL were established from histologically confirmed metastatic melanomas and passaged only four to six times before study. SM, LN, OV and BUL were obtained from Dr G Elias (Franklin Square Hospital, Baltimore, MD, USA) and cultured in Iscove's Modified Dulbecco's Medium. LM were obtained from Dr Joseph Sinkovics (University of South Florida, Tampa, FL, USA) and cultured in RPMI 1640 medium with 10% FBS. Adult primary melanocytes (Cascade Biologics/Invitrogen, Portland, OR, USA) were grown in Medium 254 supplemented with 0.5% fetal bovine serum, 3 ng ml À1 basic fibroblast growth factor, 0.2% bovine pituitary extract, 3 mg ml À1 heparin, 0.18 mg ml À1 hydrocortisone, 5 mg ml À1 insulin, 5 mg ml À1 transferrin and 10 nM endothelin-1 (human melanocyte supplement-2 from Cascade Biologics). WI-38 cells (normal human embryonic lung fibroblasts, ATCC) are an expansion from passage 9 and have a limited lifespan of 50 population doublings. Vero cells (African green monkey kidney, ATCC) were used at a relatively late passage (4150) at which they evidence transformation-related properties and tumor formation. 36 WI-38 and Vero cells were cultured in minimal essential medium with Earle's salts, 10% FBS, 1 mM sodium pyruvate and 0.1 mM nonessential amino acids.
The generation and properties of the HSV-2 mutant DPK and the revertant virus HSV-2(R) were previously described. 33 DPK is deleted in the sequences that encode the kinase function of ICP10 (also known as HSV-2 R1). The ICP10 kinase activity functions independently of the R1 activity and is required for virus growth. DPK expresses the kinase-negative (ICP10PK deleted) protein p95 under the direction of the authentic IE ICP10 promoter. 33 DPK was grown in Vero cells. Cell lysates were cleared of cell debris by centrifugation at 3000 g for 10 min. Virus was used as it is or further partially purified by centrifugation of the cell lysates at 113 000 g for 1 h followed by resuspension in minimal essential medium with Earle's salts, 1 mM sodium pyruvate and 0.1 mM nonessential amino acids, as previously described. 39 
Antibodies, pharmacological inhibitors and chemical reagents
The generation and specificity of the rabbit polyclonal antibodies to ICP10, which recognizes an epitope that is retained by both ICP10 and the PK deleted ICP10 protein p95 [22] [23] [24] [25] [26] [27] 33, 34 and H11/HspB8 32 were previously described. The following antibodies were purchased and used according to manufacturer's instructions. Antibodies to caspase-3 (recognizes both the zymogen and its cleavage products), activated caspase-3 (caspase-3 p20), calpain (p80, p78, p28), Beclin-1, ERK1/2, activated human caspase-1, and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to activated caspase-7, phosphorylated (activated) Akt (pAkt) and total Akt were purchased from Cell Signaling Technology (Danvers, MA, USA), antibody to phosphorylated (activated) ERK 1/2 (pERK1/2) from Promega, antibody to CD11b (Mac-1 m chain-biotin conjugated) from Leinco (St Louis, MO, USA), antibody to the HSV major capsid protein VP5 from Virusys Corporation (Sykesville, MD, USA) and antibody to TNF-a from R&D Systems (Minneapolis, MN, USA). Alexafluor 594-conjugated anti-mouse and Alexafluor 488-conjugated anti-rabbit secondary antibodies were purchased from Invitrogen (Carlsbad, CA, USA). Horseradish peroxidase-conjugated anti-rabbit and anti-mouse antibodies were purchased from Cell Signaling Technologies. The In situ Cell Death Detection Kit (TUNEL) with fluorescein isothiocyanatelabeled dUTP was purchased from Roche (Indianapolis, IN, USA), the calpain inhibitor PD150606 from Calbiochem (La Jolla, CA, USA) and the pancaspase inhibitor z-VAD-fmk from Sigma-Aldrich and Promega.
Virus growth
To measure virus replication in culture, the cells were infected at a moi of 0.5 pfu per cell. Adsorption was for 1 h at 4 1C (synchronized infection). At this time, virus was removed and the cells were overlaid with minimal essential medium with 0 or 10% FBS (0 h p.i.). They were collected at various times p.i. and virus was released by seven freeze-thaw cycles and sonication (60 s at 25% output power using a Sonicator/Ultrasonic processor (Misonix, Inc., Farmingdale, NY, USA)). Virus titers were determined by plaque assay on Vero cells and the results are expressed as mean pfu per cell (burst size), as described. 32 To determine the titers of infectious virus in DPK-treated xenografts, tissues (15 mg samples) collected at 7 days after the last injection were suspended in 50 ml of virus adsorption medium (PBS supplemented with 0.2% glucose and 0.2% bovine serum albumin (BSA)) and homogenized on ice using a sterile prechilled micro-pestle. The homogenates were cleared of cell debris by centrifugation (3000 g, 10 min, 4 1C) and virus titers were determined by plaque assay.
Immunofluorescence and immunohistochemistry
For immunofluorescence, cells grown on glass coverslips were fixed with 4% paraformaldehyde overnight at 4 1C. They were then blocked with 5% normal goat serum and [23] [24] [25] [26] [27] For immunohistochemistry, tumor sections were postfixed (30 min) in 4% paraformaldehyde in PBS (w/v), treated (10 min) with 0.3% H 2 O 2 to remove endogenous peroxidases, permeabilized and blocked in blocking solution (10% goat serum, 1% BSA and 0.3% Triton-X 100 in PBS) for 1 h. Sections (20 mm) were exposed overnight (4 1C) to the primary antibody diluted in blocking solution followed by horseradish peroxidase-conjugated secondary antibody diluted in 5% goat serum and 5% BSA (1 h). The reaction was developed with ImmPACT DAB substrate (Vector Laboratories) and the sections were counterstained with Mayer's hematoxylin (Sigma-Aldrich). They were dehydrated and mounted in Permount (Sigma-Aldrich). Visualization was with an Olympus BX50 microscope under brightfield conditions. The stained cells were counted in representative 50 mm 2 fields in each of four tumors/treatment and the percentage of positive cells was calculated relative to the total cells per field, as described. [23] [24] [25] [26] [27] 34, 46 Cell death and TUNEL Cell death was determined by trypan blue exclusion and staining with Ethidium homodimer-1 (EtHD-1), a cell impermeable red fluorescent nuclear stain that increases intensity after binding to the DNA of dead cells. For trypan blue staining, cells were collected by centrifugation and the pellet was resuspended in 50 ml PBS to which 50 ml trypan blue was added. Dead cells were counted by four independent hemocytometer counts. EtHD-1 staining was carried out as per manufacturer's instructions and visualized by microscopy at Â 4 magnification using a Nikon E4100 fluorescent microscope (Melville, NY, USA) using phase contrast and a Texas red (540-580 nm) cube. The stained cells were counted in five randomly selected 3 mm 2 fields (X250 cells each), and the percentage of positive cells was calculated relative to total number of cells imaged by phase contrast microscopy. 24 Detection of apoptotic DNA fragmentation with 3 0 -OH ends by TUNEL assay used the In situ Cell Death Detection kit (Roche) as per the manufacturer's instructions.
Immunoblotting
Cultured cells were lysed with radioimmunoprecipitation buffer (RIPA; 20 mM Tris-HCl (pH 7.4), 0.15 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate) supplemented with protease and phosphatase inhibitor cocktails (Sigma-Aldrich) and sonicated twice for 30 s at 25% output power with a Sonicator ultrasonic processor (Misonix, Inc.). Xenograft tissues were weighed, resuspended in RIPA buffer (0.5 ml g À1 ),
homogenized using a pre-chilled motorized pestle (Kontes, Vineland, NJ, USA) and cleared of cell debris by centrifugation (10 000 g; 4 1C for 30 min). Protein concentrations were determined by the bicinchoninic assay (Pierce, Rockford, IL, USA) and 100 mg protein samples were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Immunoblotting was as previously described. [22] [23] [24] [25] [26] [27] 33, 34, [51] [52] [53] [54] Briefly, membranes were blocked (1 h, room temperature) in 5% nonfat milk in TN-T buffer (0.01 M Tris-HCl pH 7.4, 0.15 M NaCl, 0.05% Tween-20), exposed (1 h) to primary antibodies, washed in TN-T buffer and incubated (1 h) in horseradish peroxidaseconjugated secondary antibodies. Detection was with ECL reagents (Amersham, Pittsburg, PA, USA) and highperformance chemiluminescence film (Hyperfilm ECL, Amersham). Quantitation was by densitometric scanning with the Bio-Rad GS-700 imaging densitometer (Bio-Rad, Hercules, CA, USA). The results of three independent experiments are expressed as the mean actin-adjusted densitometric units ± s.d.
In vivo studies.
The Animal Care and Use Committee of the University of Maryland School of Medicine approved all the described studies. Male nude mice (6 to 8-week-old) (Balb/c nu/nu) were obtained from Charles River Laboratories (Wilmington, MA, USA). To establish subcutaneous melanoma xenograft models, nude mice were given A2058, A375 or LM melanoma cells (10 7 in 100 ml) by subcutaneous injection into both the left and right hind flanks. When the tumors became palpable (B200 mm 3 in volume; day 14 for A2058 and day 7 for A375 and LM xenografts), animals were randomly assigned to treatment groups. Treatments consisted of intratumoral injections of partially purified DPK (10 6 or 10 7 pfu) in a total volume of 100 ml of cell culture medium or 100 ml of virus-free culture medium (control). The treatment protocol consisted of four injections given at weekly intervals (one injection per week). Every other day, minimum and maximum perpendicular tumor axes were measured with microcalipers and tumor volume was calculated using the formula: volume ¼ ((length Â width 2 )/2). Animals were maintained in pathogen-free conditions and were euthanized when their tumors reached 1.5 cm in any one direction. Tissues were collected after euthanasia, and processed for virus titration, staining and immunoblotting.
Statistical analysis
Analysis of variance (ANOVA) was carried out with SigmaStat version 3.1 for Windows (Systat Software, Point Richmond, CA, USA). Tumor volumes were compared over time between untreated and treated groups by pairwise two-way ANOVA followed by the Tukey's honestly significant difference test. KaplanMeier survival analysis was carried out with 1.5 cm of tumor growth in any one dimension as the terminal event and curve comparison was by Log-Rank (MantelCox) analysis.
